Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
19 Results for "
CaV2.2
" in MedChemExpress (MCE) Product Catalog:
Products (19)
19 Results for "CaV2.2" in MCE Product Catalog:
1
1 Cited Publications
Target:
Research Areas:
Cav 2.2 blocker 1 (compound 9) is a N-type calcium channel (Cav 2.2) blocker for the treatment of pain, with an IC50 of 1 nM .
Cat. No.: HY-120751
CAS No.: 1309601-26-0
Target:
Research Areas:
TROX-1 is a selective, orally active and brain-penetrant N-type calcium channel (Cav2.2) inhibitor with an IC50 value of 0.11 μM. TROX-1 exerts state-dependent and use-dependent inhibition, preferentially targets open/inactivated channels, blocks depolarization-associated calcium influx, and fully blocks calcium influx in rat dorsal root ganglion neurons. TROX-1 reverses inflammatory-induced hyperalgesia, nerve injury-induced allodynia. TROX-1 can be used for the research of pain .
Cat. No.: HY-164803
CAS No.: 1281060-70-5
Target:
Research Areas:
CBD3063 is a selective modulator of collapsin response mediator protein 2 (CRMP2). CBD3063 uncouples Cav2.2 from CRMP2. CBD3063 reverses neuropathic and inflammatory pain by reducing membrane expression of CaV2.2 .
Target:
Research Areas:
Cav 2.2 blocker 2 is a Cav2.2 calcium channel blocker extracted from patent WO2017046581A1, compound 1. Cav 2.2 blocker 2 can reverses hyperalgesia associated with an injury or inflammation in conjunction with the opioid .
Target:
Research Areas:
BTT-266 is an antagonist forcalcium channel, through suppression of the CaVα1-AID-CaVβ3 interaction, with a Ki of 1.4 μM. BTT-266 modulates the activation of voltage-dependent CaV2.2. BTT-266 exhibits analgesic efficacy against neuropathic pain in rats model .
Cat. No.: HY-P3269
CAS No.: 178805-91-9
Target:
Research Areas:
Target:
Research Areas:
MONIRO-1 is a T-type and N-type calcium channel blocker with IC50 values of 34, 3.3, 1.7 and 7.2 µM against hCav2.2, hCav3.1, hCav3.2 and hCav3.3, respectively. MONIRO-1 has low activity against L-type calcium channels. MONIRO-1 can be used for the study of pain and epilepsy .
Cat. No.: HY-148866
CAS No.: 2143584-82-9
Target:
Research Areas:
Cavα2δ1&NET-IN-3 (example 216) is an inhibitor of the subunit α2δ of voltage-gated calcium channels (VGCC) and noradrenaline transporter (NET). Cavα2δ1&NET-IN-3 has Kis of 100-500 nM for human α2δ-1 subunit of Cav2.2 calcium channel and NET, respectively .
Cat. No.: HY-147639
CAS No.: 2987640-67-3
Target:
Research Areas:
Cav 2.2/3.2 blocker 1 (Compound 9e) is a neuronal calcium channel blocker with IC50 values of 78 μM and 80 μM against Cav2.2 and Cav3.2, respectively. Cav 2.2/3.2 blocker 1 can penetrate the CNS .
Cat. No.: HY-P10898
CAS No.: 2900996-95-2
Target:
Research Areas:
Cat. No.: HY-169845
CAS No.: 687568-35-0
Target:
Research Areas:
Calcium Channel antagonist 6 (Compound 328) is a highly selective antagonist of voltage-gated calcium channel CaV2.2 with an IC50 value of 0.37 μM. Calcium Channel antagonist 6 inhibits of neuron depolarization-induced Ca 2+ influx. Calcium Channel antagonist 6 is promising for research of neuropathic pain .
Cat. No.: HY-181612
Research Areas:
COX-2/CaV2.2-IN-1 is an orally active and selective dual COX-2/CaV2.2 inhibitor, exhibiting a COX-2 IC50 of 0.26 μM and a CaV2.2 IC50 of 0.29 μM. COX-2/CaV2.2-IN-1 suppresses inflammatory responses and inflammatory mediator (IL-6, TNF-α, NO) production. COX-2/CaV2.2-IN-1 produces pronounced analgesic effects in diverse models of inflammatory, neuropathic, and visceral pain. COX-2/CaV2.2-IN-1 can be used for the research of chronic pain .
Cat. No.: HY-RS01792
Target:
Research Areas:
CACNA1B Human Pre-designed siRNA Set A contains three designed siRNAs for CACNA1B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-115596
CAS No.: 2413939-96-3
Target:
Research Areas:
BTT-369 is a CaVα1·CaVβ3 protein-protein complex antagonist with a Ki of 2.0 μM. BTT-369 inhibits CaV2.2 currents, with an apparent IC50 value of 31 μM. BTT-369 disrupts the interaction between CaVα1 and CaVβ3 subunits. BTT-369 reduces the current density of CaV2.2, and shifts the voltage dependence of steady-state inactivation and activation of CaV2.2 to more positive potentials. BTT-369 alleviates mechanical hyperalgesia in a rat model of tibial nerve injury. BTT-369 can be used for the study of neuropathic pain .
Cat. No.: HY-P5874
Target:
Research Areas:
Cat. No.: HY-P5813
Synonyms: β-TRTX-cd1a; β-Theraphotoxin-cd1a
Target:
Research Areas:
Cat. No.: HY-N12768
CAS No.: 37720-87-9
Target:
(Ericaceae) (RM). Rhodojaponin VI binds rat N-Ethylmaleimide-sensitive fusion (NSF) with a Kd of 1.03 μM. Rhodojaponin VI blocks the MDM2-Notch1 signalling pathway by reducing MDM2 and Notch1 expression. Rhodojaponin VI indirectly reduces Cav2.2 current intensity by inhibiting NSF-mediated Cav2.2 trafficking. Rhodojaponin VI alleviates glomerulonephritis progression and podocyte injury in passive heymann nephritis rats. Rhodojaponin VI also has antinociceptive effects. Rhodojaponin VI can be used for the researches of heymann nephritis and pain .
Cat. No.: HY-120751A
CAS No.: 2751591-42-9
Target:
Research Areas:
(S)-TROX-1 is the S-enantiomer of TROX-1 (HY-120751). TROX-1 is a selective, orally active and brain-penetrant N-type calcium channel (Cav2.2) inhibitor with an IC50 value of 0.11 μM. TROX-1 exerts state-dependent and use-dependent inhibition, preferentially targets open/inactivated channels, blocks depolarization-associated calcium influx, and fully blocks calcium influx in rat dorsal root ganglion neurons. TROX-1 reverses inflammatory-induced hyperalgesia, nerve injury-induced allodynia. TROX-1 can be used for the research of pain .
Cat. No.: HY-180400
CAS No.: 1426293-61-9
Target:
Research Areas:
PAM-2 is a potent, orally active, CNS-penetrant selective α7 nAChR positive allosteric modulator (human α7 nAChR EC50: 39 μM, rat α7 nAChR EC50: 12 μM) with anti-nociceptive and anti-inflammatory activity. PAM-2 exhibits selectivity over α9α10 nAChR (IC50 = 174 μM) and CaV2.2 channel (IC50 = 89 μM). PAM-2 decreases Streptozotocin (STZ) (HY-13753)- and Oxaliplatin (HY-17371)-inducned nuroparhic pain in mice by α7 nAChR potentiation. PAM-2 can be used for the research of neuropathic pain .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
